Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
Insmed launched BRINSUPRI 25 mg tablets (brensocatib hydrate) commercially in Japan for non-cystic fibrosis bronchiectasis in adults and patients 12 years and older. The launch follows MHLW approval in August 2026 based on the Phase 3 ASPEN study, and BRINSUPRI is now the first and only approved, commercially available NCFB treatment in Japan.
Key figures
- Drug Name
- BRINSUPRI (brensocatib hydrate)
- Phase Of Trial
- Phase 3 (ASPEN, basis of approval)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.